GenoScreen and ScienceVision announce an agreement to commercialize the Deeplex® Myc-TB test in Malaysia, Myanmar and Brunei.
With 10 million new cases per year, and 1.4 million deaths in 2019, tuberculosis remains the world's deadliest bacterial infectious disease. The emergence and spread of multidrug-resistant mycobacterial strains (causing more than 400,000 new cases in 2019) are causing a global public health problem that complicates the fight against TB. Southeast Asia is one of the most affected regions in the world, accounting for more than 40% of global TB cases and deaths.
Deeplex® Myc-TB is an innovative test for predicting antibiotic resistance in Mycobacterium tuberculosis developed by GenoScreen. It allows, thanks to its innovative deep sequencing engineering, to simultaneously study the resistance to 15 antibiotic molecules. This test is based on the amplification and targeted sequencing of more than 20 genetic regions of the pathogen. It allows a complete diagnosis of the antibiotic resistance profile and the genotype of the bacteria, from a clinical sample, without a prior culture step.
Through this agreement, GenoScreen confirms its commitment to the fight against this pandemic.
